Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability
| Autor: | Daniel Pella, Robert Hatala, Rastislav Sidlo, Katarina Hatalova |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Relative risk reduction
Adult Male medicine.medical_specialty Fixed-dose combination Urology Blood Pressure 030204 cardiovascular system & hematology Cohort Studies 03 medical and health sciences 0302 clinical medicine Risk Factors Diabetes mellitus medicine Perindopril Edema Humans Pharmacology (medical) 030212 general & internal medicine Amlodipine Longitudinal Studies Prospective Studies Antihypertensive Agents Aged business.industry General Medicine Middle Aged medicine.disease Drug Combinations Mean blood pressure Blood pressure Tolerability Diabetes Mellitus Type 2 Anesthesia Hypertension Female business medicine.drug |
| Zdroj: | Clinical drug investigation. 36(7) |
| ISSN: | 1179-1918 |
| Popis: | Although single-pill, fixed-dose combinations (FDCs) are widely endorsed for the reduction of blood pressure and cardiovascular risk, studies to date have not evaluated the differences between FDCs and free associations using matched drugs and doses. The objective of this study was to determine whether switching from a free association of perindopril/amlodipine to the FDC formulation led to significant improvements in efficacy and tolerability. In this subanalysis of the previously published SYMBIO study, we looked at the effect of switching patients from a free association of perindopril/amlodipine to an equivalent dose of FDC (N = 335). In the SYMBIO study, concomitant antihypertensive medications were allowed; however, they remained unchanged till the end of the study. Blood pressure was measured at baseline, 1, and 3 months. Targets were defined as blood pressure |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink